Evolus, Inc. released its Q2 2023 earnings report, providing granular revenue breakdown data that illuminates Jeuveau's market position relative to Allergan Aesthetics' Botox and Galderma's Dysport. The filing offers practitioners a window into how the third-major toxin is tracking in the competitive landscape—critical for practices evaluating rebate programs and supply-chain partnerships.
Injectables
Evolus Q2 2023: Revenue Breakdown Signals Jeuveau Stabilization
Toxin maker's earnings reveal where Jeuveau stands against Botox and Dysport in competitive market.
1-YEAR MOVE
EOLS
▼15.6%
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Evolus's Q2 breakdown reveals where Jeuveau stands in the three-toxin market—critical data for rebate negotiations.
Jeuveau's performance reflects the reality of the modern toxin market: differentiation on onset speed and diffusion profile matters less than rebate depth and practitioner loyalty. Evolus has leaned into aggressive Aspire rebate positioning to gain shelf space, particularly among independent practices seeking alternatives to AbbVie's Alle ecosystem. The Q2 data helps practices benchmark their own Jeuveau utilization against market averages and assess whether the toxin's economics justify continued inventory commitment.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.